Georgia Hatzivassiliou, Ph.D. - Publications

Affiliations: 
2001 Columbia University, New York, NY 
Area:
Genetics, Molecular Biology, Oncology

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Xiao Y, Kwong M, Daemen A, Belvin M, Liang X, Hatzivassiliou G, O'Brien T. Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable. Plos One. 11: e0164166. PMID 27711204 DOI: 10.1371/journal.pone.0164166  0.32
2016 Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, Kwong M, Hong R, Gao M, Del Nagro C, Pusapati R, Ma S, Salphati L, Pang J, Zhou A, ... ... Hatzivassiliou G, et al. Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nature Chemical Biology. PMID 27479743 DOI: 10.1038/nchembio.2143  0.32
2016 Gnad F, Wallin J, Edgar K, Doll S, Arnott D, Robillard L, Kirkpatrick DS, Stokes MP, Vijapurkar U, Hatzivassiliou G, Friedman LS, Belvin M. Quantitative phosphoproteomic analysis of the PI3K-regulated signaling network. Proteomics. PMID 27282143 DOI: 10.1002/pmic.201600118  0.32
2016 Gnad F, Doll S, Song K, Stokes MP, Moffat J, Liu B, Arnott D, Wallin J, Friedman LS, Hatzivassiliou G, Belvin M. Phosphoproteome analysis of the MAPK pathway reveals previously undetected feedback mechanisms. Proteomics. PMID 27273156 DOI: 10.1002/pmic.201600119  0.32
2016 Ghosh S, Taylor A, Chin M, Huang HR, Conery AR, Mertz JA, Salmeron A, Dakle PJ, Mele D, Cote A, Jayaram H, Setser JW, Poy F, Hatzivassiliou G, DeAlmeida-Nagata D, et al. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. The Journal of Biological Chemistry. PMID 27056325 DOI: 10.1074/jbc.M115.708560  0.32
2016 Pusapati RV, Daemen A, Wilson C, Sandoval W, Gao M, Haley B, Baudy AR, Hatzivassiliou G, Evangelista M, Settleman J. mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells. Cancer Cell. PMID 27052953 DOI: 10.1016/j.ccell.2016.02.018  0.32
2016 Foster SA, Whalen DM, Özen A, Wongchenko MJ, Yin J, Yen I, Schaefer G, Mayfield JD, Chmielecki J, Stephens PJ, Albacker LA, Yan Y, Song K, Hatzivassiliou G, Eigenbrot C, et al. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. Cancer Cell. PMID 26996308 DOI: 10.1016/j.ccell.2016.02.010  0.32
2015 Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, Kowanetz K, Hong R, Moffat J, Gao M, Boudreau A, Mroue R, Corson L, O'Brien T, Qing J, ... ... Hatzivassiliou G, et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors Proceedings of the National Academy of Sciences of the United States of America. 112: E4410-E4417. DOI: 10.1073/pnas.1501605112  0.32
2014 Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, Forrest WF, Kwong M, Hedehus M, Hatzivassiliou G, Friedman LS, Phillips HS. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proceedings of the National Academy of Sciences of the United States of America. 111: 14217-22. PMID 25225364 DOI: 10.1073/pnas.1409653111  0.32
2013 Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, Hewitt JF, Zak M, Peck A, Orr C, Merchant M, Hoeflich KP, Chan J, Luoh SM, Anderson DJ, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 501: 232-6. PMID 23934108 DOI: 10.1038/nature12441  0.32
2012 McCleland ML, Adler AS, Shang Y, Hunsaker T, Truong T, Peterson D, Torres E, Li L, Haley B, Stephan JP, Belvin M, Hatzivassiliou G, Blackwood EM, Corson L, Evangelista M, et al. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Research. 72: 5812-23. PMID 23139210 DOI: 10.1158/0008-5472.CAN-12-1098  0.32
2012 Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Molecular Cancer Therapeutics. 11: 1143-54. PMID 22402123 DOI: 10.1158/1535-7163.MCT-11-1010  0.32
2012 Mathieu S, Gradl SN, Ren L, Wen Z, Aliagas I, Gunzner-Toste J, Lee W, Pulk R, Zhao G, Alicke B, Boggs JW, Buckmelter AJ, Choo EF, Dinkel V, Gloor SL, ... ... Hatzivassiliou G, et al. Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties. Journal of Medicinal Chemistry. 55: 2869-81. PMID 22335519 DOI: 10.1021/jm300016v  0.32
2011 Wenglowsky S, Ren L, Ahrendt KA, Laird ER, Aliagas I, Alicke B, Buckmelter AJ, Choo EF, Dinkel V, Feng B, Gloor SL, Gould SE, Gross S, Gunzner-Toste J, Hansen JD, ... Hatzivassiliou G, et al. Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors. Acs Medicinal Chemistry Letters. 2: 342-7. PMID 24900315 DOI: 10.1021/ml200025q  0.32
2011 Anderson DJ, Durieux JK, Song K, Alvarado R, Jackson PK, Hatzivassiliou G, Ludlam MJ. Live-cell microscopy reveals small molecule inhibitor effects on MAPK pathway dynamics. Plos One. 6: e22607. PMID 21829637 DOI: 10.1371/journal.pone.0022607  0.32
2010 Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 464: 431-5. PMID 20130576 DOI: 10.1038/nature08833  0.32
2009 Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science (New York, N.Y.). 324: 1076-80. PMID 19461003 DOI: 10.1126/science.1164097  0.32
2008 Bobrovnikova-Marjon E, Hatzivassiliou G, Grigoriadou C, Romero M, Cavener DR, Thompson CB, Diehl JA. PERK-dependent regulation of lipogenesis during mouse mammary gland development and adipocyte differentiation. Proceedings of the National Academy of Sciences of the United States of America. 105: 16314-9. PMID 18852460 DOI: 10.1073/pnas.0808517105  0.32
2008 DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism. 7: 11-20. PMID 18177721 DOI: 10.1016/j.cmet.2007.10.002  0.32
2006 Shaknovich R, Basso K, Bhagat G, Mansukhani M, Hatzivassiliou G, Murty VV, Buettner M, Niedobitek G, Alobeid B, Cattoretti G. Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling. Haematologica. 91: 1313-20. PMID 17018379  0.32
2005 Thompson CB, Bauer DE, Lum JJ, Hatzivassiliou G, Zong WX, Ditsworth D, Zhao F, Buzzai M, Lindsten T. How do cancer cells acquire the fuel needed to support cell growth? Cold Spring Harbor Symposia On Quantitative Biology. 70: 357-362. PMID 16869772 DOI: 10.1101/sqb.2005.70.011  0.32
2005 Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 8: 311-21. PMID 16226706 DOI: 10.1016/j.ccr.2005.09.008  0.32
2005 Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 24: 6314-22. PMID 16007201 DOI: 10.1038/sj.onc.1208773  0.32
2005 Buzzai M, Bauer DE, Jones RG, DeBerardinis RJ, Hatzivassiliou G, Elstrom RL, Thompson CB. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation Oncogene. 24: 4165-4173. PMID 15806154 DOI: 10.1038/sj.onc.1208622  0.32
2005 Hatzivassiliou G, Andreadis C, Thompson CB. Akt-directed metabolic alterations in cancer Drug Discovery Today: Disease Mechanisms. 2: 255-262. DOI: 10.1016/j.ddmec.2005.05.007  0.32
2003 Falini B, Tiacci E, Pucciarini A, Bigerna B, Kurth J, Hatzivassiliou G, Droetto S, Galletti BV, Gambacorta M, Orazi A, Pasqualucci L, Miller I, Kuppers R, Dalla-Favera R, Cattoretti G. Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). Blood. 102: 3684-92. PMID 12881317 DOI: 10.1182/blood-2003-03-0750  0.32
2003 Zong WX, Li C, Hatzivassiliou G, Lindsten T, Yu QC, Yuan J, Thompson CB. Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis Journal of Cell Biology. 162: 59-69. PMID 12847083 DOI: 10.1083/jcb.200302084  0.32
2003 Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Dalla-Favera R. IRTA family proteins: Transmembrane receptors differentially expressed in normal B cells and involved in lymphomagenesis Annals of the New York Academy of Sciences. 987: 312-313.  0.32
2002 Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Dalla-Favera R. IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells. Blood. 99: 2662-9. PMID 11929751 DOI: 10.1182/blood.V99.8.2662  0.32
2001 Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S, Tagawa S, Taniwaki M, Russo J, Neri A, Cattoretti G, Clynes R, Mendelsohn C, Chaganti RS, Dalla-Favera R. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 14: 277-89. PMID 11290337 DOI: 10.1016/S1074-7613(01)00109-1  0.32
1997 Cooper MJ, Lippa M, Payne JM, Hatzivassiliou G, Reifenberg E, Fayazi B, Perales JC, Morrisn LJ, Templeton D, Piekarz RL, Tan J. Safety-modified episomal vectors for human gene therapy Proceedings of the National Academy of Sciences of the United States of America. 94: 6450-6455. PMID 9177238 DOI: 10.1073/pnas.94.12.6450  0.32
1994 Cooper MJ, Hatzivassiliou G, Miron S. A rapid, PCR-based assay for episomal replication Biotechniques. 16: 20-24. PMID 8136130  0.32
1994 Cooper MJ, Haluschak JJ, Johnson D, Schwartz S, Morrison LJ, Lippa M, Hatzivassiliou G, Tan J. p53 Mutations in bladder carcinoma cell lines Oncology Research. 6: 569-579. PMID 7787250  0.32
Show low-probability matches.